USA – OPDP Plots Research on Indication, Endpoint Perceptions in Cancer Drug TV Ads

As more biopharma companies turn to television advertising to showcase cancer treatments, the US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) is planning new research to better understand how viewers comprehend the treatments’ indications and endpoints.

One study will help OPDP determine whether disclosing information about the endpoints supporting a cancer drug’s indications actually helps consumers understand the drug’s efficacy.

For the study, OPDP will create two television ads for fictitious cancer drugs — one for non-small cell lung cancer and one for multiple myeloma — with audio claims about overall survival, overall response rate with and without a disclosure, or progression-free survival with and without a disclosure…